SA
AZN icon

SpiderRock Advisors’s AstraZeneca AZN Stock Holding History

SpiderRock Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Hold
0
– -$3K – 48
2017
Q3 		– Hold
0
– – – 557

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SpiderRock Advisors's AZN Position: Q3 2024 in Review

SpiderRock Advisors increased its AstraZeneca (AZN) stake by 328% in Q3 2024, buying an estimated $2.22M and bringing the position to 17,951 shares worth $2.8M. The position accounts for 0.04% of the portfolio, ranked #251.

SpiderRock Advisors first reported a position in AZN in Q1 2024 and has held it in 3 quarters since. 1,229 funds tracked by Wall St. Rank hold AZN as of Q3 2024.

  • SpiderRock Advisors held 17,951 shares of AstraZeneca worth $2.8M as of Q3 2024.
  • SpiderRock Advisors bought 13,752 AstraZeneca shares in Q3 2024, an estimated $2.22M.
  • AstraZeneca made up 0.04% of SpiderRock Advisors's portfolio in Q3 2024, its #251 holding.
  • SpiderRock Advisors first reported a position in AstraZeneca in Q1 2024 and has held it in 3 quarters since.
  • 1,229 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2024.

Based on SpiderRock Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.